Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $21.7100 (-2.65%) ($21.4400 - $22.7500) on Thu. Nov. 19, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.14% (three month average) | RSI | 76 | Latest Price | $21.7100(-2.65%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.1% a day on average for past five trading days. | Weekly Trend | FOLD advances 6.9% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(52%) IWO(49%) XBI(48%) IWM(46%) IWC(44%) | Factors Impacting FOLD price | FOLD will decline at least -1.57% in a week (0% probabilities). VIXM(-28%) VXX(-13%) UUP(-11%) UNG(-5%) TLT(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.57% (StdDev 3.14%) | Hourly BBV | -2 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | 5 Day Moving Average | $22.26(-2.47%) | 10 Day Moving Average | $21.91(-0.91%) | 20 Day Moving Average | $20.5(5.9%) | To recent high | -4.2% | To recent low | 68.6% | Market Cap | $5.606b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |